Tumor-associated antigens - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 161

[75] Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating muta-
tion of D835 within the activation loop of FLT3 in human hematologic malignancies.
Blood 2001;97:2434-9.
[76] Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with
irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-
stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Proc Natl Acad Sci USA 1993;90:3539-43.
[77] Soiffer R, et al. Vaccination with irradiated, autologous melanoma cells engineered to
secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated
gene transfer augments antitumor immunity in patients with metastatic melanoma.
J Clin Oncol 2003;21:3343-50.
[78] Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the
graft-versus-tumor effect through posttransplant immunization with granulocyte-
macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood
2000;95:3011-9.
[79] Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, et al. Granulocyte-
macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy
in combination with autologous stem cell transplantation (ASCT) as postremission
therapy for acute myeloid leukemia (AML). Blood 2009;114:1736-45.
[80] Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri
XN, et al. Circulating blood dendritic cells from myeloid leukemia patients display
quantitative and cytogenetic abnormalities as well as functional impairment. Blood
2001;98:3750-6.
[81] Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, et al.
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic
cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation
clinical trial. Cytotherapy 2009:1-6.
[82] Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K,
et al. Induction of complete and molecular remissions in acute myeloid leukemia by
Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA
2010;107:13824-9.
[83] Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing
machines. Cell 2001;106:255-8.
[84] Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, et al.
Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic
leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res
2002;62:2861-8.
[85] Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, et al. Immunotherapy using
autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute
myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
J Clin Apher 2004;19:66-70.
[86] Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, et al. Vaccination
of B-CLL patients with autologous dendritic cells can change the frequency of leukemia
antigen-specific CD8 + T cells as well as CD4 + CD25 + FoxP3 + regulatory T cells toward an
antileukemia response. Leukemia 2008;22:1007-17.
[87] Ochsenreither S, Fusi A, Geikowski A, Stather D, Busse A, Stroux A, et al. Wilms' tumor
protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta
sequence associated with remission in one patient is detectable in other vaccinated
patients. Cancer Immunol Immunother CII 2012;61:313-22.
[88] Nicholson E, Ghorashian S, Stauss H, Improving TCR. Gene therapy for treatment of
haematological malignancies. Adv Hematol 2012;2012:1-1.
[89] Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer
regression in patients after transfer of genetically engineered lymphocytes. Science
2006;314(5796):126-9.
[90] Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene
therapy with human and mouse T-cell receptors mediates cancer regression and targets
normal tissues expressing cognate antigen. Blood 2009;114:535-46.
[91] Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor
regression in patients with metastatic synovial cell sarcoma and melanoma using ge-
netically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
[92] Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, et al. Development of a Wilms'
tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can
eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 2010;95:126-34.
[93] Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, et al. Novel adoptive T-cell
immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous
TCRs shows marked antileukemia reactivity and safety. Blood 2011;118:1495-503.

163